BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 18980984)

  • 1. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.
    Murillo O; Arina A; Hervas-Stubbs S; Gupta A; McCluskey B; Dubrot J; Palazón A; Azpilikueta A; Ochoa MC; Alfaro C; Solano S; Pérez-Gracia JL; Oyajobi BO; Melero I
    Clin Cancer Res; 2008 Nov; 14(21):6895-906. PubMed ID: 18980984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
    Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
    J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.
    Murillo O; Dubrot J; Palazón A; Arina A; Azpilikueta A; Alfaro C; Solano S; Ochoa MC; Berasain C; Gabari I; Pérez-Gracia JL; Berraondo P; Hervás-Stubbs S; Melero I
    Eur J Immunol; 2009 Sep; 39(9):2424-36. PubMed ID: 19662633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.
    Dubrot J; Palazón A; Alfaro C; Azpilikueta A; Ochoa MC; Rouzaut A; Martinez-Forero I; Teijeira A; Berraondo P; Le Bon A; Hervás-Stubbs S; Melero I
    Int J Cancer; 2011 Jan; 128(1):105-18. PubMed ID: 20309938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
    Simeone E; Ascierto PA
    J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
    Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
    J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.
    Gauttier V; Judor JP; Le Guen V; Cany J; Ferry N; Conchon S
    Int J Cancer; 2014 Dec; 135(12):2857-67. PubMed ID: 24789574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.
    Murillo O; Arina A; Tirapu I; Alfaro C; Mazzolini G; Palencia B; López-Diaz De Cerio A; Prieto J; Bendandi M; Melero I
    Clin Cancer Res; 2003 Nov; 9(15):5454-64. PubMed ID: 14654524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
    Guillerey C; Ferrari de Andrade L; Vuckovic S; Miles K; Ngiow SF; Yong MC; Teng MW; Colonna M; Ritchie DS; Chesi M; Bergsagel PL; Hill GR; Smyth MJ; Martinet L
    J Clin Invest; 2015 May; 125(5):2077-89. PubMed ID: 25893601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers.
    Westwood JA; Matthews GM; Shortt J; Faulkner D; Pegram HJ; Duong CP; Chesi M; Bergsagel PL; Sharp LL; Huhn RD; Darcy PK; Johnstone RW; Kershaw MH
    Leuk Res; 2014 Aug; 38(8):948-54. PubMed ID: 24934848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy.
    Wilcox RA; Flies DB; Wang H; Tamada K; Johnson AJ; Pease LR; Rodriguez M; Guo Y; Chen L
    Cancer Res; 2002 Aug; 62(15):4413-8. PubMed ID: 12154048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.
    Guillerey C; Nakamura K; Pichler AC; Barkauskas D; Krumeich S; Stannard K; Miles K; Harjunpää H; Yu Y; Casey M; Doban AI; Lazar M; Hartel G; Smith D; Vuckovic S; Teng MW; Bergsagel PL; Chesi M; Hill GR; Martinet L; Smyth MJ
    JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31194697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
    May KF; Chen L; Zheng P; Liu Y
    Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance.
    Foell JL; Diez-Mendiondo BI; Diez OH; Holzer U; Ruck P; Bapat AS; Hoffmann MK; Mittler RS; Dannecker GE
    Immunology; 2004 Sep; 113(1):89-98. PubMed ID: 15312139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD137-mediated immunotherapy for allergic asthma.
    Polte T; Foell J; Werner C; Hoymann HG; Braun A; Burdach S; Mittler RS; Hansen G
    J Clin Invest; 2006 Apr; 116(4):1025-36. PubMed ID: 16528411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.
    John LB; Howland LJ; Flynn JK; West AC; Devaud C; Duong CP; Stewart TJ; Westwood JA; Guo ZS; Bartlett DL; Smyth MJ; Kershaw MH; Darcy PK
    Cancer Res; 2012 Apr; 72(7):1651-60. PubMed ID: 22315352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
    Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
    An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.